Regimen Reference Order – CUTA – encorafenib + binimetinib

ARIA: CUTA - [encorafenib + binimetinib]

Planned Course: **Until disease progression or unacceptable toxicity (1 cycle = 30 days)**
Indication for Use: **Melanoma BRAF mutation positive, Metastatic**

Proceed with treatment if:

- ***ANC equal to or greater than 1.2 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***
- ***Total bilirubin less than 1.5 times upper limit of normal***

If binimetinib is held for toxicity, contact oncologist for direction on encorafenib dose reduction

- **Contact Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – CUTA – encorafenib and binimetinib

Drug	Dose	CCMB Administration Guideline
encorafenib	450 mg*	Orally once daily with or without food Take at the same time as morning dose of binimetinib Swallow whole **(Self-administered at home)**
binimetinib	45 mg	Orally twice daily with or without food Swallow whole **(Self-administered at home)**

*If binimetinib is held for toxicity, single agent encorafenib should be reduced to a maximum of 300 mg once daily until binimetinib is resumed

encorafenib (BRAFTOVI®) available dosage strength: 75 mg capsule
Classification: Cytotoxic, Hazardous

binimetinib (MEKTOVI®) available dosage strength: 15 mg tablet
Classification: Cytotoxic, Hazardous

REQUIRED MONITORING

Cardiac monitoring

- EKG and Left Ventricular Ejection Fraction (LVEF) monitoring recommended
  - At baseline
  - Every 3 to 6 months during treatment at the physician's discretion

All Cycles

- CBC, serum creatinine, electrolytes, liver enzymes, total bilirubin, blood glucose and creatinine phosphokinase (CK) as per Physician Orders
- Clinical ocular and skin toxicities assessment
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O_2 saturation) with each clinic visit

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

INSTRUCTIONS FOR PATIENT

- binimetinib doses should be taken approximately 12 hours apart
- Patients should report signs and symptoms of bleeding/hemorrhage
- encorafenib and binimetinib can cause cutaneous and ocular toxicities. Patient should be instructed to notify clinic if they experience rash or eye problems
- This regimen has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce applicable safe handling precautions of medications, blood and body fluids during encorafenib and binimetinib treatment

ADDITIONAL INFORMATION

- This regimen has been associated with venous thromboembolism (VTE) events
- encorafenib and binimetinib can prolong QT interval and cause left ventricular dysfunction
- binimetinib has been associated with interstitial lung disease and pneumonitis
- binimetinib can cause hypertension
- rhabdomyolysis has been reported with binimetinib
- encorafenib has been associated with the development of new primary malignancies (cutaneous and non-cutaneous)
- encorafenib and binimetinib will be dispensed by CCMB Pharmacy